Evopoint Biosciences Gets CDE Approval for Phase I/II Study of XNW27011 ADC
Suzhou Evopoint Biosciences Co., Ltd., a China-based pharmaceutical company, has announced receiving approval from the...
China’s NHC Advances Enhanced Recovery After Surgery (ERAS) Protocols Nationwide
The National Health Commission (NHC) has released a notification with the goal of promoting enhanced...
ChengDu ShengNuo Biotech Secures NMPA Approval for Generic Firazyr Equivalent
ChengDu ShengNuo Biotech Co., Ltd (SHA: 688117), a China-based polypeptide specialist, has announced that it...
CanSino Biotechnology Leads RMB 500 Million Private Equity Fund for Vaccine Investments
China-based vaccines specialist CanSino Biotechnology Inc., (HKG: 6185) has announced plans to invest RMB 140...
PharmaEssentia Corporation Completes Secondary Offering of GDR Shares on Luxembourg Exchange
Taiwan-based PharmaEssentia Corporation (TPE: 6446) has announced the successful closing of a secondary offering of...
Lee’s Pharmaceutical Holdings Ltd Reports 2022 Revenues and Pipeline Updates
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its 2022 financial report, recording HKD...
Reistone Biopharma’s RSS0343 Receives NMPA Approval for Non-Cystic Fibrosis Bronchiectasis
Reistone Biopharma Co., Ltd, a company incubated by Hengrui Pharmaceuticals (SHA: 600276) with an investment...
Siemens Healthineers and China Chest Pain Center Launch Smart Training Program
German healthcare giant Siemens Healthineers (ETR: SHL) has partnered with the China Chest Pain Center...
Neurodawn Pharmaceutical’s Y-1 Receives NMPA Approval for Primary Intracranial Tumor Treatment
Nanjing-based Neurodawn Pharmaceutical Co., Ltd has announced that its Category 1 drug, injectable Y-1, has...
Biosion Secures Series B+ Financing to Advance Antibody-Based Therapies Pipeline
Biosion, a global, clinical-stage biotech company dedicated to developing antibody-based therapies for immune and oncologic...
Jiangsu Hengrui Pharmaceuticals Reports 2022 Revenue Dip and Increased R&D Investment
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a China-based pharmaceutical company, has released its 2022 financial report,...
GenScript Biotech’s Subsidiary Legend Biotech Announces Positive CAR-T Therapy Results
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...
HealZen Therapeutics and NeuShen Seal Deal for Global Rights to CNS Drug Programs
China-based HealZen Therapeutics has entered into a licensing agreement with compatriot firm NeuShen, focusing on...
AACR 2023 Highlights: CAR-T Therapies and Monoclonal Antibody Combinations in Cancer Research
The 2023 edition of the American Association for Cancer Research (AACR) annual meeting has concluded,...
Hasten Biopharmaceutical Secures $315 Million Investment for Pipeline Expansion
China-based Hasten Biopharmaceutical Co., Ltd has reportedly received USD 315 million in a fundraising round...
Staidson Pharmaceutical Plans RMB 580 Million Private Placement for Drug R&D
China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced plans to raise RMB 580...
Sangon Biotech Secures RMB 2 Billion in First Financing Round to Boost Life Science Services
China-based contract research organization (CRO) Sangon Biotech has secured RMB 2 billion (USD 290.3 million)...
Shenzhen 01 Life Science Secures RMB 100 Million in Series B1 Financing for Microecology Platform
Shenzhen 01 Life Science and Technology Ltd. Co., Ltd, a company specializing in human big...
Pfizer’s Prevenar 13 Receives Expanded Age Range Approval in China
U.S.-based pharmaceutical giant Pfizer (NYSE: PFE) has reported receiving an additional indication approval from the...
BeiGene’s Tislelizumab-Chemo Combo Excels in RATIONALE 305 Trial for Gastric Cancer
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), a China-based biopharmaceutical company, has announced that the...